期刊文献+

Post-marketing Surveillance for Combined Oral Contraceptive Containing Desogestrel(Marvelon~) in Chinese Rural Areas 被引量:1

Post-marketing Surveillance for Combined Oral Contraceptive Containing Desogestrel(Marvelon~) in Chinese Rural Areas
原文传递
导出
摘要 To assess the side effects and the continuation rate of combined oral contraceptive (COC) containing desogestrel (Marvelon) during 12 months. Methods This was a post-marketing surveillance study on Marvelon COC among 870 healthy rural women in 5 different counties of Jiangsu Province during 12 months. Results About 24.02% of the women who used Marvelon COC experienced side effects during 12 months. Gastrointestinal disorder, bleeding/spotting and chloasma were ranked the first three in the side effects. The rate of side effects of Marvelon COC users during the first 3 months in southern area of Jiangsu was significantly higher than that of users in northern area of Jiangsu. Most of the users did not experience obvious weight changes i.e., loss or increase in weight of more than 5 kg during 12 months. Blood pressure and biochemical indicators of almost 99% among users were within the normal range. The gross cumulative continuation rate for 12 months was 83.14%; the most common medical reason for discontinuation was gastrointestinal disorder. There was an increased risk of discontinuation use among women with lower educational level. Conclusion Marvelon COC brought fewer side effects and was well accepted when applied in Chinese rural women. To assess the side effects and the continuation rate of combined oral contraceptive (COC) containing desogestrel (Marvelon) during 12 months. Methods This was a post-marketing surveillance study on Marvelon COC among 870 healthy rural women in 5 different counties of Jiangsu Province during 12 months. Results About 24.02% of the women who used Marvelon COC experienced side effects during 12 months. Gastrointestinal disorder, bleeding/spotting and chloasma were ranked the first three in the side effects. The rate of side effects of Marvelon COC users during the first 3 months in southern area of Jiangsu was significantly higher than that of users in northern area of Jiangsu. Most of the users did not experience obvious weight changes i.e., loss or increase in weight of more than 5 kg during 12 months. Blood pressure and biochemical indicators of almost 99% among users were within the normal range. The gross cumulative continuation rate for 12 months was 83.14%; the most common medical reason for discontinuation was gastrointestinal disorder. There was an increased risk of discontinuation use among women with lower educational level. Conclusion Marvelon COC brought fewer side effects and was well accepted when applied in Chinese rural women.
出处 《Journal of Reproduction and Contraception》 CAS 2008年第4期193-200,共8页 生殖与避孕(英文版)
基金 funded by the National Tenth Five-year Key Project (2002BA709B06)
关键词 combined oral contraceptive DESOGESTREL side effects continuation rate combined oral contraceptive desogestrel side effects continuation rate
  • 相关文献

参考文献10

  • 1.Guidelines for Surveillance, Prevention and Treatment for Adverse Reaction of Contraceptives[]..2003
  • 2Liu YR.The contraceptive prevalence and trend in Chinese married women of reproductive age (part four)[].Chinese Journal of Family Planning.2004
  • 3Chen JK,Qu QM,He CH, et al.Clinical comparative study of three different kind low-dose combined oral contraceptives[].Reproduction and Contraception.1987
  • 4Chen J,Smith KB,Morrow S, et al.The acceptability of combined oral hormonal contraceptives in Shanghai, People’s Republic of China[].Contraception.2003
  • 5Geissler KH.Hormonelle Contrazeption mit Marvelon[].Fortschritte der Medizin.1983
  • 6Bilotta P,Favilli S.Clinical evaluation of a monophasic ethinylestradiol/desogestrel containing oral contraceptive[].Arzneimittelfors.1988
  • 7Benagiano G.Comparison of two monophasic oral contraceptives:g estodene/ethinylestradiolv ersusd esogestrel/ethinylestradiol[].International Journal of Fertility.1989
  • 8Walling M.A multicenter efficacy and safety study of an oral contraceptive containing150mg desogestrel and30mg ethinylestradiol[].Contraception.1992
  • 9Fotherby K.Twelve years of clinical experience with an oral contraceptive containing30mg ethinylo estradiol and150mg desogestrel[].Contraception.1995
  • 10J. Endrikat U. M&#xfc,ller and B. D&#xfc,sterberg.A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, with respect to efficacy, cycle control, and tolera[].Contraception.1997

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部